2.605
price up icon3.17%   0.08
after-market アフターアワーズ: 2.59 -0.015 -0.58%
loading

Galectin Therapeutics Inc (GALT) 最新ニュース

pulisher
09:54 AM

Non-Alcoholic Steatohepatitis Market to Show Remarkable - openPR

09:54 AM
pulisher
Oct 29, 2024

Psoriasis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart

Oct 29, 2024
pulisher
Oct 29, 2024

Liver Cirrhosis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Recent Developments | Astrazeneca, Bayer, Sanofi, Pfizer, Merck, Novartis - Barchart

Oct 29, 2024
pulisher
Oct 29, 2024

Liver Cirrhosis Pipeline Trends 2024: Clinical Trials, - openPR

Oct 29, 2024
pulisher
Oct 28, 2024

LIVER CIRRHOSIS MARKET TO GROW AT A SUBSTANTIAL GROWTH RATE - openPR

Oct 28, 2024
pulisher
Oct 23, 2024

Galectin therapeutics director Eldred Kary buys $1,300 in stock By Investing.com - Investing.com South Africa

Oct 23, 2024
pulisher
Oct 23, 2024

Galectin therapeutics director Eldred Kary buys $1,300 in stock - Investing.com

Oct 23, 2024
pulisher
Oct 17, 2024

Galectin therapeutics director Freeman buys $27,000 in stock By Investing.com - Investing.com Canada

Oct 17, 2024
pulisher
Oct 16, 2024

Galectin therapeutics director Freeman buys $27,000 in stock - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Galectin Therapeutics Inc. (NASDAQ:GALT) Director Purchases $13,500.00 in Stock - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at StockNews.com - Defense World

Oct 15, 2024
pulisher
Oct 15, 2024

Application Monitoring Suites Market Size and Industry Overview - News in Assen

Oct 15, 2024
pulisher
Oct 15, 2024

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - The Manila Times

Oct 15, 2024
pulisher
Oct 15, 2024

Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: - openPR

Oct 15, 2024
pulisher
Oct 15, 2024

Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail

Oct 15, 2024
pulisher
Oct 15, 2024

Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail

Oct 15, 2024
pulisher
Oct 15, 2024

Nonalcoholic Steatohepatitis Treatment Market Size, Innovations Driving Market Evolution (2024-2034) - IndiaPolitics.com

Oct 15, 2024
pulisher
Oct 14, 2024

Marshall Wace LLP Buys New Shares in Security National Financial Co. (NASDAQ:SNFCA) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

Marshall Wace LLP Cuts Stock Holdings in ARC Document Solutions, Inc. (NYSE:ARC) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

AXT, Inc. (NASDAQ:AXTI) Stock Holdings Trimmed by Marshall Wace LLP - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

The Manufacturers Life Insurance Company Has $951,000 Stock Holdings in Huntsman Co. (NYSE:HUN) - Defense World

Oct 14, 2024
pulisher
Oct 14, 2024

Marshall Wace LLP Buys New Holdings in Hanesbrands Inc. (NYSE:HBI) - Defense World

Oct 14, 2024
pulisher
Oct 06, 2024

Research Analysts’ Updated EPS Estimates for October 6th (APVO, CNP, FDX, FLNT, FRD, GALT, HOPE, KBR, LSXMK, NVGS) - Defense World

Oct 06, 2024
pulisher
Oct 06, 2024

Galectin Therapeutics (NASDAQ:GALT) Rating Increased to Hold at StockNews.com - Defense World

Oct 06, 2024
pulisher
Oct 06, 2024

Galectin Therapeutics (NASDAQ:GALT) Upgraded at StockNews.com - MarketBeat

Oct 06, 2024
pulisher
Oct 04, 2024

Global Non-Alcoholic Steatohepatitis Treatment Market Overview And Statistics For 2024-2033 - EIN News

Oct 04, 2024
pulisher
Oct 02, 2024

Ipsen's IQIRVO Approval Has Intensified the Primary Biliary Cholangitis Market Space | DelveInsight - The Malaysian Reserve

Oct 02, 2024
pulisher
Oct 02, 2024

Rhumbline Advisers Purchases New Holdings in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Oct 02, 2024
pulisher
Sep 30, 2024

Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference - The Manila Times

Sep 30, 2024
pulisher
Sep 30, 2024

Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra - The Manila Times

Sep 30, 2024
pulisher
Sep 29, 2024

Galectin Therapeutics (FRA:PHPN) Interest Expense : €-3.71 Mil (TTM As of Jun. 2024) - GuruFocus.com

Sep 29, 2024
pulisher
Sep 29, 2024

Galectin Therapeutics (FRA:PHPN) Change In Prepaid Assets : €-0.16 Mil (TTM As of Jun. 2024) - GuruFocus.com

Sep 29, 2024
pulisher
Sep 28, 2024

StockNews.com Lowers Galectin Therapeutics (NASDAQ:GALT) to Sell - MarketBeat

Sep 28, 2024
pulisher
Sep 27, 2024

Bank of New York Mellon Corp Purchases Shares of 64,423 Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Sep 27, 2024
pulisher
Sep 26, 2024

Galectin 3 Market: Report Trends and Future Forecast Until (2024-2034) - Apiculture Market: Report ...

Sep 26, 2024
pulisher
Sep 25, 2024

Global Non Alcoholic Steatohepatitis Market to Hit $ 108428.91 Million by 2032, Growing at 60.1% CAGR - 대구포스트

Sep 25, 2024
pulisher
Sep 21, 2024

Galectin Therapeutics (FRA:PHPN) Enterprise Value : €217.44 Mil (As of Sep. 21, 2024) - GuruFocus.com

Sep 21, 2024
pulisher
Sep 21, 2024

Galectin Therapeutics (NASDAQ:GALT) Upgraded to “Hold” at StockNews.com - Defense World

Sep 21, 2024
pulisher
Sep 18, 2024

Cirrhosis Pipeline Insights, Clinical Trials, Treatment Drugs, and Companies 2024 - openPR

Sep 18, 2024
pulisher
Sep 17, 2024

Commonwealth Equity Services LLC Buys 367,610 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World

Sep 17, 2024
pulisher
Sep 17, 2024

Commonwealth Equity Services LLC Purchases 367,610 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - MarketBeat

Sep 17, 2024
pulisher
Sep 17, 2024

Head-To-Head Analysis: Galera Therapeutics (NASDAQ:GRTX) & Galectin Therapeutics (NASDAQ:GALT) - Defense World

Sep 17, 2024
pulisher
Sep 16, 2024

Non-Alcoholic Steatohepatitis Treatment Market Insights Discussed Regarding Report 2024: Detailed Analysis ... - WhaTech

Sep 16, 2024
pulisher
Sep 09, 2024

Galectin Therapeutics Unveils Future Plans and Drug Potential - TipRanks

Sep 09, 2024
pulisher
Sep 04, 2024

Hepatic Cirrhosis Market: Epidemiology, Therapies, - openPR

Sep 04, 2024
pulisher
Sep 04, 2024

Short Interest in Galectin Therapeutics Inc. (NASDAQ:GALT) Increases By 6.4% - Defense World

Sep 04, 2024
pulisher
Sep 04, 2024

North America Galectin Inhibitor Therapeutics Market By Application : Industry Analysis and Forecast 2031 - அக்னி செய்திகள்

Sep 04, 2024
pulisher
Sep 03, 2024

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Sep 03, 2024
pulisher
Sep 03, 2024

Rectify Pharmaceuticals Appoints Pol Boudes as Chief Medical Officer - GlobeNewswire

Sep 03, 2024
pulisher
Sep 02, 2024

Galectin Therapeutics Inc. (NASDAQ:GALT) Sees Significant Growth in Short Interest - MarketBeat

Sep 02, 2024
pulisher
Sep 02, 2024

Its Stock Has Paid Off Big Time For Galectin Therapeutics Inc - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

How did Galectin Therapeutics Inc (GALT) fare last session? - US Post News

Sep 02, 2024
pulisher
Aug 30, 2024

Investors Buy Large Volume of Put Options on Galectin Therapeutics (NASDAQ:GALT) - Defense World

Aug 30, 2024
pulisher
Aug 29, 2024

Stock Traders Purchase Large Volume of Put Options on Galectin Therapeutics (NASDAQ:GALT) - MarketBeat

Aug 29, 2024
pulisher
Aug 27, 2024

Galectin Therapeutics executive buys $8,050 in company stock By Investing.com - Investing.com Australia

Aug 27, 2024
pulisher
Aug 26, 2024

Galectin Therapeutics executive buys $8,050 in company stock - Investing.com India

Aug 26, 2024
pulisher
Aug 19, 2024

Analysts Set Expectations for Galectin Therapeutics Inc.'s Q1 2025 Earnings (NASDAQ:GALT) - MarketBeat

Aug 19, 2024
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
大文字化:     |  ボリューム (24 時間):